J&J mops up $900M in waste, writing off the last big chunk of the $1.75B it spent to acquire Alios

Back in the fall of 2014, Alios looked like quite a find for J&J, with its lead RSV drug and some early stage hep C programs as a group of rivals fought over the blockbuster market that awaited the winner of that contest.

Now, more than 4 years after J&J plunked down $1.75 billion in cash to acquire little Alios, J&J is folding its hand and walking away from what proved a bad bet. After writing off $630 million for AL-8176 last year, the pharma giant has come back to to eliminate the remaining $900 million, with nothing to show for it.

The news was tastefully buried in a quiet SEC filing.

We learned last fall that J&J had shuttered the Phase IIb trials for RSV as they returned to a preclinical stage of development. J&J had noted:

This decision was made due to the ongoing analysis of new preclinical data and the need to perform further pre-clinical studies. Generation and analysis of these data is anticipated to require additional time.

A decision on further clinical trials for lumicitabine will be made once the evaluation of the data has been completed.

J&J bought out the biotech after taking a close look at its Phase II data.

As for hep C, Gilead won that race, coming up with a painless cocktail to cure the disease. After reaching a quick sales peak, that mountain of revenue has been dwindling away, with little left for the remaining commercial rivals in the field.

RSV, meanwhile, has been a graveyard for drug developers, claiming a lineup of failed programs in recent years.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->